2028 Competition FDA 
Pharmaceutical Technology
SEPTEMBER 15, 2022
According to GlobalData’s report, Paxlovid, the company’s small-molecule Covid-19 oral therapy, was shown to reduce Covid-19 infections by 32% in adults and is forecast to be the top-selling drug by total sales, generating $81bn between 2021 and 2028. AbbVie reported a 22.7% Bristol Myers Squibb (BMS) documented a 9.1%
pharmaphorum
AUGUST 4, 2022
Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in with a $3.7 billion bid to buy out the company.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 2, 2022
Now, Roche has an opportunity to add ease of administration to the competitive profile of Tecentriq, reducing the time patients have to spend in clinics and potentially reducing the cost of treatment. Also coming through is Pfizer, which partners with Germany’s Merck KGaA on latecomer PD-L1 drug Bavencio (avelumab).
Pharmaceutical Technology
APRIL 20, 2023
The district court had previously blocked Sandoz and Zydus from producing, selling, offering to sell, or importing generic versions of Otezla until February 2028. This is one of several patent infringement cases Amgen has pursued in recent years to stave competition. billion worth of the drug worldwide. Patent No.
Pharmaceutical Technology
MAY 19, 2023
Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. However, in the second year of biosimilar competition, Rituxan sales started to significantly erode. Rituxan’s success made it a prime target for biosimilar developers.
PM360
SEPTEMBER 21, 2023
Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.
Pharmaceutical Technology
OCTOBER 28, 2022
In June 2021, the FDA approved Pfizer’s Prevnar 20 for adult use, although a nod for paediatric use is pending. Merck, known outside of the US and Canada as MSD, is developing its portfolio of pneumococcal vaccines , and has secured an FDA approval for the paediatric use of its 15-serotype vaccine Vaxneuvance in June.
Expert insights. Personalized for you.
108 
Let's personalize your content